+91-8668442535

Bispecific Antibodies Market By Type (Immunoglobulin G (IgG) Like Molecule, Non Immunoglobulin G (IgG) Like Molecule), by Application (Oncology, Autoimmune Disease, Others) - Growth, Future Prospects & Competitive Analysis, 2018 – 2026

Industry Outlook

The bispecific antibodies market is set to grow with a compounded annual growth rate (CAGR) of 5.9% during the forecast period from 2018 to 2026. According to the research findings presented by the World Health Organization (WHO), in 2018, cancer was responsible for the deaths of approximately 9.6 million people throughout the globe. The severe adverse effects related to chemotherapy led to the development of bispecific antibodies for the treatment of cancer. Currently, two drugs are approved by the U.S. Food and Drug Administration: catumaxomab and blinatumomab. Thirty bispecific antibodies are in the pipeline and are undergoing clinical trial studies. The competition exerted by monoclonal antibodies for the treatment of the same disease condition acts as a major limitation for the bispecific antibody market's growth.

Market Synopsis

The IgG-like molecule market is driven by a longer serum half-life and an excellent cytotoxicity profile.

An immunoglobulin G (IgG)-like molecule is leading the type segment for the bispecific antibodies market. An IgG-like molecule such as catumaxomab (Fresenius Biotech and Trion Pharma) is widely employed for the treatment of malignant ascites due to its inherent features, such as its longer serum half-life and excellent cytotoxicity profile. Non-IgG-like molecules will be the fastest-growing market during the forecast period owing to the recent launch of blinatumomab (Amgen, Inc.) for the treatment of refractory B-cell acute lymphoblastic leukemia on account of its smaller half-life and enhanced tissue penetration characteristics.

Severe adverse effects related to the current treatment regime and the burgeoning requirement for targeted drug delivery drive the oncology market's growth.

Oncology currently dominates the application segment of the market for bispecific antibodies. The factors responsible for its growth are the severe adverse effects related to the current treatment regimen and the burgeoning requirement of targeted drug delivery for the treatment of cancer. Bispecific antibodies have the ability to cater to the current requirement in cancer treatment by redirecting immune effector cells towards tumor cells, blocking signaling pathways, and targeting tumor angiogenesis. Autoimmune diseases such as plaque psoriasis and rheumatoid arthritis will be treated in the near future by employing bispecific antibodies such as IL-6RHAS (Ablynx) and IL-17A/F (Merck Group) that block the proinflammatory cytokines. A few bispecific antibodies are in the pipeline, which will be utilized for the treatment of ailments such as wet age-related macular degeneration (AMD) and idiopathic pulmonary fibrosis.

Increasing mortality and a lack of effective treatment for cancer drive the bispecific antibody market in North America.

North America is currently leading the geographical segment for the bispecific antibody market. The major attributes responsible for the dominance of North America are increasing mortality and a lack of effective treatment for cancer. According to the Centers for Disease Control and Prevention (CDC), cancer is the second-largest cause of mortality in the United States, resulting in 1 in 4 deaths due to the disease. The bispecific antibody market in Europe is driven by factors such as increased funding by government healthcare agencies in drug discovery and cancer prevention programs. The domicile of key players such as Merck Group, F. Hoffmann-La Roche AG, and Janssen Global Services, LLC, etc., provides impetus to the growth of bispecific antibodies in Europe. Asia Pacific is set to register positive growth during the forecast period of 2018–2026 owing to the rising prevalence of cancer and a supportive regulatory environment for the approval and distribution of bispecific antibodies.

Periods of History and Forecast

This research report presents the analysis of each segment from 2016 to 2026, considering 2017 as the base year for the research. The compound annual growth rate (CAGR) for each of the respective segments is calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

In the scope of the report, the market is segmented as follows:

Biopharmaceutical companies providing bispecific antibodies are Amgen, Inc.; Ablynx; Eli Lilly and Company; F.Hoffman La-Roche AG; Janssen Global Services, LLC; Merck Group; Merrimack Pharmaceuticals; Neovii Biotech; OncoMed Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals.

Key questions are answered in this report.

  • Who are the key biopharmaceutical companies manufacturing bispecific antibodies?
  • What are the drivers, opportunities, and restraints pertaining to the market for bispecific antibodies?
  • What is the disease etiology of different forms of cancer, and what is the mechanism of action of bispecific antibodies?
  • Which type is the largest and fastest growing in the market for bispecific antibodies?
  • Which application is the largest and fastest growing in the bispecific antibody market?
  • Which regional segment is the leading and fastest-growing one in the bispecific antibodies market?

Frequently Asked Questions:

The market for Bispecific Antibodies Market is expected to reach US$ XX Mn by 2026.

The Bispecific Antibodies Market is expected to see significant CAGR growth over the coming years, at 5.9%.

The report is forecasted from 2018-2026.

The base year of this report is 2017.

Ablynx; Eli Lilly and Company; F.Hoffman La-Roche AG; Janssen Global Services, LLC; Merck Group; Merrimack Pharmaceuticals; Neovii Biotech; OncoMed Pharmaceuticals, Inc. are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  Dec 2018
Category:  Pharmaceuticals
Report ID:   59497
Report Format:   PDF
Pages:   120
Rating:    4.2 (49)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support